source clustersSource Clusters is the single source of information on regional development in the life sciences sector worldwide.

With content providing broad overviews as well as in-depth coverage of business development trends, company activities, life science cluster collaborations, multi-partner scientific projects and its extensive news coverage, Source Clusters presents the latest management, research, technology and regional development information serving the needs of executives in the internationally growing life sciences sector.

Source Clusters is the essential resource for companies, incubators, science parks, clusters and regional development agencies looking to find a new location or attract new business and exploit new opportunities across the life sciences sector.

Cobra Biologics appoints Dr Darrell Sleep as Director of Innovation

Cobra Biologics Darrel Sleep 15.1.19Biologics CDMO Cobra Biologics has appointed Dr Darrell Sleep as Director of Innovation as part of the company’s on-going strategic expansion activities currently underway at its Keele, UK site, in which it is increasing its capacity and capability for both clinical and commercial supply of viral vector and DNA products to advanced therapy medicinal product developers.

In his new role, Sleep will lead the site’s innovation team, which has been newly formed from the integration of existing in-house R&D and process development expertise. The combined innovation team will deliver contract development activities to customers in addition to driving scientific and technical innovation for new and existing service offerings. Sleep will work closely with Professor Daniel Smith, the company’s CSO, to streamline process workflows and facilitate timely adoption of new bioprocessing solutions. The company says the appointment supports the rapid process development approaches required by Cobra’s advanced therapies customers that are essential for cost-effective clinical and commercial manufacturing.

Sleep has 30 years of experience in the biopharmaceutical field, with a proven record for leading innovation and product development. This includes 20 years in management positions where he successfully led a team to develop a new technology platform delivering preclinical in-vivo proof-of-concept data sets, established techniques to improve therapeutic index and secured the relevant intellectual property to facilitate a number of successful collaborations with major pharmaceutical companies. He has also managed the development of improved production systems for a product, which, following technology transfer from R&D to Operations, successfully entered cGMP manufacture. In addition, he is co-inventor of a technology platform designed to improve the circulatory half-life of biotherapeutic drugs, which led to the development of approved biologics and generated royalties of more than $30 million by end 2017.

For further information about Cobra Biologics visit

Last modified onTuesday, 29 January 2019 10:20

Related items

Latest from Tom Mulligan